For clinicians, the most valuable outcome will be the data packet the FDA releases: seeing exactly what evidence they reviewed and what specific safety risks they identified will give us unprecedented clarity on where this peptide actually stands
The peptide sequence, derived from human growth hormone, appears sufficiently similar to native proteins that the immune system does not mount a response against it
It lowers the kinetic energy, reducing the chances of bond breakage and preserving the peptide's structure
The premise behind TRT is achieving stable male androgen levels to help facilitate anabolic processes
Neurological Relevance Preclinical evidence suggests broader neuroprotective potential: In traumatic brain injury models, SS-31 reduced mitochondrial swelling, neuronal loss, and neuroinflammation Aged mice treated with SS-31 showed significantly improved exercise tolerance, muscle strength, and mitochondrial efficiency Studies demonstrate protection against ischemic injury and enhanced cardiac output Phase 3 trials are ongoing for dry age-related macular degeneration and primary mitochondrial myopathy (Stealth BioTherapeutics pipeline) Implications for Brain Aging Mitochondrial dysfunction is a hallmark of brain aging and neurodegeneration
DSIP is a nine-residue naturally occurring peptide studied in sleep-related neuroregulatory research
